Local disease control after stereotactic body radiotherapy in patients with neuroendocrine neoplasms: a cohort study

Figures & data

Table 1. WHO 2019 classification of GEP-NEN and WHO 2021 classification of BP-NEN.

GEP-NEN			BP-NEN
Grade	Mitotic count^a	Ki-67 index (%)	Grade	Mitotic count^a	Ki67 index (%)
NET G1	<2	<3	TC	0–1	≥5%	Well-differentiated
NET G2	2–20	3–20	AC	2–10	≥30%
NET G3	>20	>20
Large cell NEC	>20	>20	Large cell NEC	>10	40–80%	Poorly differentiated
Small cell NEC	<20	>20	SCLC	>10	50–100%

^aper 10 high power field (HPF).

GEP: Gastroenteropancreatic; BP: Bronchopulmonary; NET: Neuroendocrine tumour; NEC: Neuroendocrine carcinoma; TC: Typical Carcinoid; AC: Atypical Carcinoid; SCLC: Small cell lung cancer.

Table 2. Pt. characteristics.

	Number (n)	%
Gender
Male	8	38
Female	13	62
Age at treatment start (mean; range)	69 (39–86)
WHO performance status
0	7	33
1	7	33
2	2	10
3	1	5
N/A	4	19
Primary tumour
Lung	14	67
Small intestine	3	14
Pancreas	1	5
Rectum	1	5
Unknown primary	2	9
Morphology
Large cell	4	19
Typical carcinoid	6	28
Atypical carcinoid	1	5
Neuroendocrine, not further specified	10	48
Ki67 index %
<3	7	33
3–20	5	24
>20	7	33
N/A	2	10
Grade
1–2	12	57
3, NEC	7	33
N/A	2	10
Metastases at time of diagnosis
Yes	8	38
No	13	62
Treatment prior to SBRT
SSA	2	10
Chemotherapy	3	14
Surgery	2	9
Surgery + SSA	1	5
Chemotherapy + PRRT	1	5
Surgery + SSA + PRRT	1	5
None	11	53

Table 3. SBRT characteristics (BED₁₀, prescribed dose and treatment site).

	Number	%
BED10, median (range)	118,11 Gy (95,2–219.68)
Prescribed dose (Gray/Fractions/Fractions per week)
45Gy/3 Fr/2w	5	24
48Gy/3 Fr/2w	1	5
56Gy/8 Fr/3w	4	19
61.8 Gy/3 Fr/2w	2	9
67.5 Gy/3 Fr/2w	9	43
Treatment site
Primary tumour (lung)	11	53
Metastatic site (liver and lung)	10	47
Liver	9	43
Lung	1	4
Prescribed dose >60 Gy according to treatment site
Lung (n = 12)	7	58
Liver (n = 9)	5	44

Figure 1. The swimmerplot illustrates follow-up time and events (local failure, systemic failure and death) of each patient respectively.

Figure 2. Survival curves. The Kaplan-Meier curves demonstrates the three-year local control (A), PFS (B) and OS (C) for all of the patients included and available at follow-up after three years or more.

Data availability statement

The data that support the findings of this study is available upon reasonable request from the corresponding author (ADN). The data are not publicly available as they contain information that could compromise the privacy of research participations.